Trial reportJournal of neuro-oncology2021
Extent of resection and survival outcomes in World Health Organization grade II meningiomas.
Trial report in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up.Journal of neuro-oncology · 2025Article
- Article
- Characteristics of optic canal invasion in the large midline non-tuberculum sellae anterior skull base meningiomas and the surgical outcomes.Acta neurochirurgica · 2025Article
- Risk factors associated with higher WHO grade in meningiomas: a multicentric study of 552 skull base meningiomas.Scientific reports · 2025Article
- Postoperative microcystic meningioma of the fourth ventricle with subsequent giant cell reparative granuloma: a case report.Frontiers in oncology · 2025Article
- Multiomic and clinical analysis of multiply recurrent meningiomas reveals risk factors, underlying biology, and insights into evolution.Science advances · 2024Article
- Atypical and anaplastic meningiomas in the later decades of life: A national cancer database analysis.Acta neurochirurgica · 2024Article
- Surgical Management of High-Grade Meningiomas.Cancers · 2024Review
- Grading meningioma resections: the Simpson classification and beyond.Acta neurochirurgica · 2024Review
- Intraoperative Imaging and Optical Visualization Techniques for Brain Tumor Resection: A Narrative Review.Cancers · 2023Review
- Review
- Post Surgical Management of WHO Grade II Meningiomas: Our Experience, the Role of Gamma Knife and a Literature Review.Life (Basel, Switzerland) · 2022Article
- Why we need new classification models in meningioma management.Acta neurochirurgica · 2022Article
- Molecular determinants of outcomes in meningiomas.Frontiers in oncology · 2022Review
- Extent of resection and survival outcomes in the World Health Organization Grade II meningiomas.Surgical neurology international · 2022Article
- DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study.Frontiers in oncology · 2022Article
- Establishment and Validation of an Integrated Model to Predict Postoperative Recurrence in Patients With Atypical Meningioma.Frontiers in oncology · 2021Article
- Long-term outcomes of active surveillance after DOTATATE PET/MRI-confirmed gross total resection in WHO grade 2 meningioma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWHO grade II meningiomas behave aggressively, with recurrence rates as high as 60%. Although complete resection in low-grade meningiomas is associated with a relatively low recurrence rate, the impact of complete resection for WHO grade II meningiomas is less clear. We studied the association of extent of resection with overall and progression-free survivals in patients with WHO grade II meningiomas.
methodsA retrospective database review was performed to identify all patients who underwent surgical resection for intracranial WHO grade II meningiomas at our institution between 1995 and 2019. Kaplan-Meier analysis was used to compare overall and progression-free survivals between patients who underwent gross total resection (GTR) and those who underwent subtotal resection (STR). Multivariable Cox proportional-hazards analysis was used to identify independent predictors of tumor recurrence and mortality.
resultsOf 214 patients who underwent surgical resection for WHO grade II meningiomas (median follow-up 53.4 months), 158 had GTR and 56 had STR. In Kaplan-Meier analysis, patients who underwent GTR had significantly longer progression-free (p = 0.002) and overall (p = 0.006) survivals than those who underwent STR. In multivariable Cox proportional-hazards analysis, GTR independently predicted prolonged progression-free (HR 0.57, p = 0.038) and overall (HR 0.44, p = 0.017) survivals when controlling for age, tumor location, and adjuvant radiation.
conclusionsExtent of resection independently predicts progression-free and overall survivals in patients with WHO grade II meningiomas. In an era of increasing support for adjuvant treatment modalities in the management of meningiomas, our data support maximal safe resection as the primary goal in treatment of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.